UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis

Microbiology spectrum, 2023-12, Vol.11 (6), p.e0237123-e0237123

2023

Volltextzugriff (PDF)

In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection

Clinical microbiology and infection, 2022-03, Vol.28 (3), p.447.e1-447.e6

2022

Volltextzugriff (PDF)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

Infection and drug resistance, 2018-01, Vol.11, p.1309-1320

2018

Volltextzugriff (PDF)

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Microbiology spectrum, 2024-04, Vol.12 (4), p.e0383623-e0383623

2024

Volltextzugriff (PDF)

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015

European journal of clinical microbiology & infectious diseases, 2018-09, Vol.37 (9), p.1653-1659

2018

Volltextzugriff (PDF)

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

BMC infectious diseases, 2019-02, Vol.19 (1), p.195-12, Article 195

2019

Volltextzugriff (PDF)

Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy

Antimicrobial resistance & infection control, 2024-08, Vol.13 (1), p.91-14

2024

Volltextzugriff (PDF)

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens

Open forum infectious diseases, 2024-06, Vol.11 (6), p.ofae296

2024

Volltextzugriff (PDF)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France

JAC-antimicrobial resistance, 2021-06, Vol.3 (2), p.dlab081-dlab081

2021

Volltextzugriff (PDF)

Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates

Journal of antimicrobial chemotherapy, 2019-12, Vol.74 (12), p.3453-3461

2019

Volltextzugriff (PDF)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Antimicrobial agents and chemotherapy, 2019-01, Vol.63 (1)

2019

Volltextzugriff (PDF)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain

Journal of global antimicrobial resistance., 2021-09, Vol.26, p.292-300

2021

Volltextzugriff (PDF)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy

Journal of global antimicrobial resistance., 2021-06, Vol.25, p.390-398

2021

Volltextzugriff (PDF)

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

Journal of global antimicrobial resistance., 2024-09, Vol.38, p.71-82

2024

Volltextzugriff (PDF)

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

Journal of global antimicrobial resistance., 2021-12, Vol.27, p.1-11

2021

Volltextzugriff (PDF)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)

JAC-antimicrobial resistance, 2022-04, Vol.4 (2), p.dlac030-dlac030

2022

Volltextzugriff (PDF)

In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations

Microbiology spectrum, 2024-06, Vol.12 (8), p.e0418123

2024

Volltextzugriff (PDF)

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

Journal of global antimicrobial resistance., 2022-03, Vol.28, p.12-17

2022

Volltextzugriff (PDF)

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic

Open forum infectious diseases, 2023-07, Vol.10 (7), p.ofad329-ofad329

2023

Volltextzugriff (PDF)

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

Antimicrobial agents and chemotherapy, 2022-10, Vol.66 (10), p.e0110022-e0110022

2022

Volltextzugriff (PDF)

Study of the glucoamylase promoter in Aspergillus niger using green fluorescent protein

Microbiology (Society for General Microbiology), 1999-03, Vol.145 ( Pt 3) (3), p.729-734

1999

Volltextzugriff (PDF)

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance

Journal of antimicrobial chemotherapy, 2022-09, Vol.77 (10), p.2895-2896

2022

Volltextzugriff (PDF)

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

660. In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

Clinical microbiology and infection, 2021-05, Vol.27 (5), p.671-686

2021

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Infectious Diseases
(17)
Microbiology
(17)
Cefiderocol
(12)
Pharmacology & Pharmacy
(12)
Humans
(9)
Anti-Bacterial Agents - Pharmacology
(8)
Cephalosporins - Pharmacology
(8)
Microbial Sensitivity Tests
(8)
Gram-Negative Bacteria
(7)
Antimicrobial Resistance
(5)
Carbapenem Resistance
(5)
Anti-Bacterial Agents - Therapeutic Use
(4)
Cephalosporins
(4)
Drug Resistance, Multiple, Bacterial
(4)
Health Aspects
(4)
Methicillin
(4)
Mortality
(4)
Pneumonia
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis

In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France

Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)

In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

Study of the glucoamylase promoter in Aspergillus niger using green fluorescent protein

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection

660. In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

Suchergebnisse filtern